Chief Scientific Officer
Cornelis Melief has made significant contributions to the field of immunology, in particular cancer immunology. In 1991, he became professor at the LUMC and since then his group has been working intensively to devise new cancer therapies based on the activation of the patient’s own immune system. Before, he headed the immunology department at the Netherlands Cancer Institute (NKI). He started his career at the blood bank in Amsterdam (CLB). Cornelis is member of the Royal Netherlands Academy of Arts and Sciences. He is author of more than 450 peer-reviewed publications and inventor on more than 30 patents and patent applications.